Ustekinumab and Vedolizumab Dual Biologic Therapy in the Treatment of Crohn’s Disease
We present a case of refractory ileocolonic Crohn’s disease in a 27-year-old female treated with dual ustekinumab and vedolizumab biologic therapy. She had mucosal healing for the first time in 13 years after a 10-month treatment of ustekinumab overlapped with 6 months of vedolizumab. No side effect...
Uloženo v:
| Hlavní autoři: | , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Wiley
2017-01-01
|
| Edice: | Case Reports in Medicine |
| On-line přístup: | http://dx.doi.org/10.1155/2017/5264216 |
| Tagy: |
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|